ArticleFrontiers in microbiology2019
The Therapeutic Effect of 1,8-Cineol on Pathogenic Bacteria Species Present in Chronic Rhinosinusitis.
Article in Frontiers in microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 30 citations in OpenAlex.
- Bacterial and fungal communities and network dynamics in Otitis media patients upon 1,8-Cineol treatment.NPJ systems biology and applications · 2026Article
- Chemical Profiling, Ampicillin Interaction Patterns, and Exploratory Molecular Docking ofInternational journal of molecular sciences · 2026Article
- Differential influence of 1,8-Cineol on distinct hypoxia-related immune alterations in human monocytes.Scientific reports · 2025Article
- Effects of Eucalyptus Essential Oil on Growth, Immunological Indicators, Disease Resistance, Intestinal Morphology and Gut Microbiota inMicroorganisms · 2025Article
- Gut microbial communities in chronic rhinosinusitis patients in response to 1,8-Cineol treatment.Current research in microbial sciences · 2025Article
- Essential oils: a potential alternative with promising active ingredients for pharmaceutical formulations in chronic wound management.Inflammopharmacology · 2024Review
- Pathogenesis, Diagnosis, and Treatment of Infectious Rhinosinusitis.Microorganisms · 2024Review
- Anti-inflammatory response to 1,8-Cineol and associated microbial communities in Otitis media patients.Scientific reports · 2024Article
- Mixture design of α-pinene, α-terpineol, and 1,8-cineole: A multiobjective response followed by chemometric approaches to optimize the antibacterial effect against various bacteria and antioxidant activity.Food science & nutrition · 2024Article
- Antibacterial and Angiotensin I-Converting Enzyme (ACE) Inhibition Activities of Essential Oil from Java Cardamom (Indian journal of microbiology · 2023Article
- 1,8-Cineol (Eucalyptol) Disrupts Membrane Integrity and Induces Oxidative Stress in Methicillin-ResistantAntioxidants (Basel, Switzerland) · 2023Article
- Modes of Action of 1,8-Cineol in Infections and Inflammation.Metabolites · 2023Review
- Determination of orally administered 1,8-Cineol in nasal polyp tissues from chronic rhinosinusitis patients using gas chromatography: mass spectrometry.Scientific reports · 2023Article
- Mechanisms and Impact of Biofilms and Targeting of Biofilms Using Bioactive Compounds-A Review.Medicina (Kaunas, Lithuania) · 2021Review
- Preparation of Terpenoid-Invasomes with Selective Activity againstBiomedicines · 2020Article
- New Perspectives for Mucolytic, Anti-inflammatory and Adjunctive Therapy with 1,8-Cineole in COPD and Asthma: Review on the New Therapeutic Approach.Advances in therapy · 2020Review
- Article
- The Important Role of Volatile Components From a Traditional Chinese Medicine Dayuan-Yin Against the COVID-19 Pandemic.Frontiers in pharmacology · 2020Review
- Dynamics of the Interleukin-10 Family of Cytokines in Chronic Otitis Media Patients upon 1,8-Cineol Treatment.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic rhinosinusitis (CRS) is marked by an inflamed mucosa of sinuses and is accompanied by a significantly reduced quality of live. Since no guidelines for the treatment of CRS are available, long lasting clinical histories with health care costs adding up to dozens of billion $ annually are caused by CRS. The progression of CRS is often induced by bacterial infections and/or a shift in microbiome as well as biofilm formation. The exact microbiome alterations are still unclear and the impenetrable biofilm renders the treatment with common antibiotics ineffective. This study focuses on characterizing the microbiome changes in CRS and investigating the inhibition of biofilm growth by 1,8-Cineol, a small, non-polar and hence biofilm penetrating molecule with known antimicrobial potential. We performed MALDI-TOF MS based characterization of the microbiomes of healthy individuals and CRS patients (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.